"Indoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
| Descriptor ID |
D007211
|
| MeSH Number(s) |
D03.633.100.473
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Indoles".
Below are MeSH descriptors whose meaning is more specific than "Indoles".
This graph shows the total number of publications written about "Indoles" by people in this website by year, and whether "Indoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 2 | 3 | 5 |
| 2000 | 5 | 2 | 7 |
| 2001 | 3 | 5 | 8 |
| 2002 | 3 | 1 | 4 |
| 2003 | 3 | 4 | 7 |
| 2004 | 4 | 5 | 9 |
| 2005 | 3 | 3 | 6 |
| 2006 | 2 | 1 | 3 |
| 2007 | 2 | 0 | 2 |
| 2008 | 4 | 2 | 6 |
| 2009 | 3 | 3 | 6 |
| 2010 | 1 | 6 | 7 |
| 2011 | 5 | 3 | 8 |
| 2012 | 6 | 1 | 7 |
| 2013 | 6 | 6 | 12 |
| 2014 | 9 | 8 | 17 |
| 2015 | 8 | 6 | 14 |
| 2016 | 4 | 3 | 7 |
| 2017 | 4 | 2 | 6 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 2 | 3 |
| 2020 | 4 | 1 | 5 |
| 2021 | 4 | 2 | 6 |
| 2024 | 1 | 3 | 4 |
| 2025 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Indoles" by people in Profiles.
-
Gastrointestinal Burden in Patients With Pancreatic Insufficient Cystic Fibrosis Before and After Elexacaftor/Tezacaftor/Ivacaftor Use. Pancreas. 2025 Nov-Dec 01; 54(10):e858-e862.
-
Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial. Mol Cancer. 2025 Jun 11; 24(1):175.
-
Early nintedanib deployment in COVID-19 interstitial lung disease (ENDCOV-I): study protocol of a randomised, double-blind, placebo-controlled trial. BMJ Open Respir Res. 2025 Apr 10; 12(1).
-
Persistence of an Infectious Form of SARS-CoV-2 After Protease Inhibitor Treatment of Permissive Cells In Vitro. J Infect Dis. 2025 Feb 04; 231(1):e68-e76.
-
Oral vancomycin treatment alters levels of indole derivatives and secondary bile acids modulating the expression of mTOR pathway genes in astrocytes during EAE. Brain Behav Immun. 2025 Mar; 125:355-370.
-
A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors. CA Cancer J Clin. 2025 Mar-Apr; 75(2):141-167.
-
A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies. Clin Cancer Res. 2024 Nov 01; 30(21):4844-4855.
-
Genetic deletion or pharmacologic inhibition of histone deacetylase 6 protects the heart against ischaemia/reperfusion injury by limiting tumour necrosis factor alpha-induced mitochondrial injury in experimental diabetes. Cardiovasc Res. 2024 10 14; 120(12):1456-1471.
-
Identification of distinct stool metabolites in women with endometriosis for non-invasive diagnosis and potential for microbiota-based therapies. Med. 2025 Feb 14; 6(2):100517.
-
ATR inhibition radiosensitizes cells through augmented DNA damage and G2 cell cycle arrest abrogation. JCI Insight. 2024 Oct 08; 9(19).